• board | Enterprise Therapeutics | Treatment of respiratory diseases

Board

Amit Munshi

Amit Munshi

Chairman

Amit D. Munshi has served as a member of Arena Pharmaceuticals’ Board of Directors since June 2016, and as President and Chief Executive Officer since May 2016. More...

Dr John Ford

Dr John Ford

Chief Executive Officer

Dr John Ford has more than 18 years of ion channel, drug discovery and development experience. More...

Dr Peter Finan

Dr Peter Finan

Investor Director

Dr Peter Finan is Partner at Epidarex Capital and currently serves on the board of Clyde Bioscienes, Caldan Therapeutics, Enterprise Therpeutics and Topas Therapeutics. More...

Bart Dzikowski

Bart Dzikowski

Investor Director, NVF

Bart Dzikowski is a Managing Director at the Novartis Venture Fund and its Head of Transactions & Legal based in Basel, Switzerland. More...

Dr Alex Mayweg

Dr Alex Mayweg

Investor Director

Alex is a Partner at Versant. Alex is an accomplished leader in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S. and Asia. More...

Dr Gert-Jan Mulder MD

Dr Gert-Jan Mulder MD

Investor Director

Geert-Jan co-founded Forbion in 2006 and is currently the Managing Partner. Geert-Jan currently serves on several boards including AM-Pharma, Promedior Inc., Laboratoris Sanifit, NeRRe Therapeutics and KaNDy Therapeutics. More...

Craig Richardson

Craig Richardson

Investor Director

Craig is a Partner in IP Group’s Life Science investment team. He started his career in the pharmaceutical industry in 1998 and worked in new product development for Glaxo Wellcome More...

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2020.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in 2020.

Learn more